In postmenopausal women at high risk for developing breast cancer, raloxifene and tamoxifen are equally effective at reducing the incidence of invasive breast cancer, but tamoxifen was more effective at reducing the incidence of non-invasive breast cancer.

The rate of endometrial cancers was greater in the tamoxifen arm, but this difference did not reach significance

Raloxifene was associated with a lower risk of thromboembolic events

In deciding which agent to choose for preventing breast cancer in high-risk postmenopausal women, the many factor can be considered:

Prior hysterectomy

Acceptance of risk of non-invasive breast cancer

Risk of thromboembolic events (the study patients were highly selected to have low risk)